BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naoumov NV, Rossol S. Studies of interleukin-12 in chronic hepatitis B virus infection. J Viral Hepat. 1997;4 Suppl 2:87-91. [PMID: 9429215 DOI: 10.1111/j.1365-2893.1997.tb00185.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Vandepapelière P. THERAPEUTIC VACCINES FOR CHRONIC HEPATITIS B INFECTION. Sexually Transmitted Diseases. Elsevier; 2000. pp. 309-38. [DOI: 10.1016/b978-012663330-6/50015-2] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
2 Piazzolla G, Tortorella C, Fiore G, Fanelli M, Pisconti A, Antonaci S. Interleukin-12 p40/p70 Ratio and In Vivo Responsiveness to IFN- α Treatment in Chronic Hepatitis C. Journal of Interferon & Cytokine Research 2001;21:453-61. [DOI: 10.1089/10799900152434303] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
3 He D, Yan G, Wang Y. Serum levels of interleukin-12 in various clinical states with hepatitis B virus infection. Cellular Immunology 2012;272:162-5. [DOI: 10.1016/j.cellimm.2011.10.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
4 TrehanPati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S, Mishra SK, Sarin SK. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol. 2011;31:509-520. [PMID: 21305387 DOI: 10.1007/s10875-011-9509-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
5 Lv J, Jin Q, Sun H, Chi X, Hu X, Yan H, Pan Y, Xiao W, Tian Z, Hou J. Antiviral treatment alters the frequency of activating and inhibitory receptor-expressing natural killer cells in chronic hepatitis B virus infected patients. Mediators Inflamm. 2012;2012:804043. [PMID: 23304062 DOI: 10.1155/2012/804043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
6 Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, Williams R, Naoumov NV. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology. 2005;42:1028-1036. [PMID: 16250037 DOI: 10.1002/hep.20888] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 3.8] [Reference Citation Analysis]
7 Kumar M, Sarin SK. Systematic review: combination therapies for treatment-naïve chronic hepatitis B. Aliment Pharmacol Ther. 2008;27:1187-1209. [PMID: 18373730 DOI: 10.1111/j.1365-2036.2008.03695.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
8 Vilarrasa E, Puig L. Psoriasis: Biologic treatment and liver disease. World J Dermatol 2014; 3(4): 76-85 [DOI: 10.5314/wjd.v3.i4.76] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Seetharam A, Lisker-Melman M. Treatment of chronic hepatitis B: are we ready for combination therapy? Curr Gastroenterol Rep 2009;11:22-7. [PMID: 19166655 DOI: 10.1007/s11894-009-0004-8] [Reference Citation Analysis]
10 Piazzolla G, Tortorella C, Schiraldi O, Antonaci S. Relationship between interferon-gamma, interleukin-10, and interleukin-12 production in chronic hepatitis C and in vitro effects of interferon-alpha. J Clin Immunol 2000;20:54-61. [PMID: 10798608 DOI: 10.1023/a:1006694627907] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
11 Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013;168:609-616. [PMID: 22985451 DOI: 10.1111/bjd.12045] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
12 Kocabas CN. Do hepatitis B virus carriers develop atopic diseases? Allergy 2001;56:1100-1. [PMID: 11703227 DOI: 10.1034/j.1398-9995.2001.00377.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
13 Sennikov SV, Krysov SV, Injelevskaya TV, Silkov AN, Grishina LV, Kozlov VA. Quantitative analysis of human immunoregulatory cytokines by electrochemiluminescence method. J Immunol Methods 2003;275:81-8. [PMID: 12667672 DOI: 10.1016/s0022-1759(03)00007-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
14 Mukherjee H, Ojha D, Bag P, Chandel HS, Bhattacharyya S, Chatterjee TK, Mukherjee PK, Chakraborti S, Chattopadhyay D. Anti-herpes virus activities of Achyranthes aspera: an indian ethnomedicine, and its triterpene acid. Microbiol Res 2013;168:238-44. [PMID: 23218996 DOI: 10.1016/j.micres.2012.11.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 4.3] [Reference Citation Analysis]
15 Koh YI, Choi IS, Park CH, Ahn JS, Ji SG. The inverse association between the presence of antibody to hepatitis B surface antigen and atopy in young adults. Korean J Intern Med 2005;20:210-6. [PMID: 16295779 DOI: 10.3904/kjim.2005.20.3.210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]